Stockscreener 앱 받기
2.69
3.94%
0.15
전일 마감가:
$2.54
열려 있는:
$2.72
하루 거래량:
217.31K
Relative Volume:
1.04
시가총액:
$11.50M
수익:
-
순이익/손실:
$-15.47M
주가수익비율:
-5.38
EPS:
-0.5
순현금흐름:
$-13.51M
1주 성능:
+9.54%
1개월 성능:
+26.92%
6개월 성능:
+45.05%
1년 성능:
-72.50%
1일 변동 폭
$2.56
$2.75
1주일 범위
$2.1935
$2.75
52주 변동 폭
$1.30
$15.59
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
NLSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
2.69 | 11.50M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.64 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.37 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.07 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.08 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ltd 주식(NLSP)의 최신 뉴스
NLS Pharmaceutics Announces Strategic Merger and Financing Milestones - TipRanks
NLS Pharmaceutics CEO Issues Letter to Shareholders - marketscreener.com
NLS Pharmaceutics Transforms: $25M Backing Powers Merger Deal as Company Goes Debt-Free - Stock Titan
NLS Pharmaceutics Announces June 2025 Shareholders’ Meeting Amid Financial Losses - TipRanks
NLS Pharmaceutics Amends Merger Agreement with Kadimastem - TipRanks
Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Decreases By 56.6% - Defense World
NLS Pharmaceutics to present Mazindol study at ASCP Meeting By Investing.com - Investing.com South Africa
NLS Pharmaceutics to present Mazindol study at ASCP Meeting - Investing.com Australia
NLS Pharmaceutics (NLSP) to Showcase Promising Data on Mazindol ER | NLSP Stock News - GuruFocus
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Ma - GuruFocus
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting - Nasdaq
Breakthrough Clinical Data: New Drug Shows Dual Action Against Fentanyl Addiction and Withdrawal - Stock Titan
NLS Pharmaceutics (NASDAQ:NLSP) Trading Down 0.6% – Should You Sell? - Defense World
NLS Pharmaceutics Extends Merger Agreement with Kadimastem - TipRanks
NLS Pharmaceutics Delays Yearly Report Filing - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - ACCESS Newswire
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - ACCESS Newswire
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire
NLS Pharmaceutics Announces Board Resignation Amid Restructuring Efforts - TipRanks
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) - Aktiellt
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS (PR Newswire) - Aktiellt
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com
NLS Pharmaceutics (NLSP): Promising Preclinical Results for Mazi - GuruFocus
NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks
Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - Quantisnow
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models (PR Newswire) - Aktiellt
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - ADVFN
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
What's Going On With NLS Pharmaceutics Shares Monday? - Benzinga
NLS Pharmaceutics Secures $3 Million Financing and $25 Million Equity Facility - TipRanks
NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com
NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider
NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India
NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com Canada
NLS Pharmaceutics Announces Strategic Merger and Advances in Therapeutic Pipeline - TipRanks
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa
Nls Pharmaceutics Ltd (NLSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.37%
0.65%
자본화:
|
볼륨(24시간):